The fact that we have demonstrated for the first time an association of the upregulation of some genes such as EGLN3, SOX2, and DLL3 with aggressive MTC was due to our novel approach, considering morphological grade to stratify patients instead of RET mutational status [9, 10], as well as from using a panel of genes focused on cancer pathways instead of RNA-seq. The gene discussed is EGLN3; the disease is cancer.